Upper intestinal surveillance in familial adenomatous polyposis

doi:10.1016/0959-8049(95)00171-E

European Journal of Cancer

Volume 31, Issues 7–8, July–August 1995, Pages 1149-1153

https://doi.org/10.1016/0959-8049(95)00171-E Get rights and content

Abstract

Our understancling of the natural history of upper gastrointestinal (GI) involvement in familial adenomatous polyposis (FAP) is still evolving, although we know that the main cause of death after colectomy in FAP is upper GI malignancy, affecting 5% of patients. The aim of duodenal surveillance is to target high risk individuals and identify cancers early. We have screened 200 patients prospectively and have observed that duodenal polyposis progresses slowly, but there are some young people who have severe disease who merit close observation. We pay particular attention to endoscopic technique and histological detail, and use a duodenal staging system. Patients are offered randomisation to studies of chemopreventive agents, and those with advanced disease are considered for surgery. Successful management is inhibited by our deficient knowledge of the natural history of upper gastrointestinal polyposis, and by our inability to identify high risk individuals with histological markers rather than because of any technological deficiencies in endoscopic equipment.

References (36)

AD Spigelman et al.
Upper gastrointestinal cancer in patients with familial adenomatous polyposis
Lancet
(1989)
M Iida et al.
Natural history of fundic gland polyposis in patients with familial adenomatosis coli/Gardner's syndrome
Gastroenterology
(1985)
DG Jagelman et al.
Upper gastrointestinal cancer in familial adenomatous polyposis
Lancet
(1988)
GJ Offerhaus et al.
The risk of upper gastrointestinal cancer in familial adenomatous polyposis
Gastroenterology
(1992)
S Olschwang et al.
Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients
Cell
(1993)
FM Giardiello et al.
Phenotypic variability of familial adenomatous polyposis in 11 untreated families with identical APC gene mutation
Gastroenterology
(1994)
M Iida et al.
Natural history of duodenal lesions in Japanese patients with familial adenomatosis coli (Gardner's syndrome)
Gastroenterology
(1989)
RW Burt et al.
Upper gastrointestinal polyps in Gardner's syndrome
Gastroenterology
(1984)
L Spirio et al.
Alleles of the APC gene: an attenuated form of familial polyposis
Cell
(1993)
T Rosch et al.
Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography
Gastroenterology
(1992)

JM Church et al.

Gastroduodenal polyps in patients with familial adenomatous polyposis

Dis Colon Rectum

(1992)

S Bulow et al.

Gastroduodenal polyps in familial polyposis coli

Dis Colon Rectum

(1985)

HJ Jarvinen et al.

Gastroduodenal polyps in familial adenomatous and juvenile polyposis

Endoscopy

(1986)

RG Sarre et al.

Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps

Gut

(1987)

JG Park et al.

Risk of gastric cancer among Korean familial adenomatous polyposis (FAP) patients (meeting abstract)

T Iwama et al.

The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs: its rational treatment

Ann Surg

(1993)

J Utsunomiya et al.

Gastric lesions of familial polyposis coli

Cancer

(1974)

AD Spigelman et al.

The upper gastrointestinal tract

Cited by (65)

Hereditary cancer syndromes as model systems for chemopreventive agent development
2016, Seminars in Oncology
Citation Excerpt :
Progression to colorectal cancer occurs with nearly complete penetrance by age 40–50 years; however, malignancy in childhood does occur [65]. Patients with FAP may also develop upper gastrointestinal polyps, although these less commonly progress to malignancy as compared to colon and rectal adenomas [66–68]. Sites other than the gastrointestinal tract are at increased risk of tumors and malignancy including: thyroid, liver, brain, bone, adrenal gland, retinal pigment, and subcutaneous tissues.
Research in chemoprevention has undergone a shift in emphasis for pragmatic reasons from large, phase III randomized studies to earlier phase studies focused on safety, mechanisms, and utilization of surrogate endpoints such as biomarkers instead of cancer incidence. This transition permits trials to be conducted in smaller populations and at substantially reduced costs while still yielding valuable information. This article will summarize some of the current chemoprevention challenges and the justification for the use of animal models to facilitate identification and testing of chemopreventive agents as illustrated though four inherited cancer syndromes. Preclinical models of inherited cancer syndromes serve as prototypical systems in which chemopreventive agents can be developed for ultimate application to both the sporadic and inherited cancer settings.
The natural history of familial adenomatous polyposis syndrome: A 24 year review of a single center experience in screening, diagnosis, and outcomes
2014, Journal of Pediatric Surgery
Citation Excerpt :
In the modern era, most FAP patients are not developing colorectal cancer due to the widespread practice of early colectomy. Therefore, secondary causes of morbidity, such as duodenal adenocarcinoma are being encountered in the post-colectomy population [5]. More than half of our patients (59%) developed upper gastrointestinal (UGI) polyposis, with mean onset at age 17 years.
Understanding the natural history of Familial Adenomatous Polyposis (FAP) will guide screening and aid clinical management.
Patients with FAP, age ≤ 20 years presenting between 1987 and 2011, were reviewed for presentation, diagnosis, extraintestinal manifestations, polyp burden, family history, histology, gene mutation, surgical intervention, and outcome.
One hundred sixty-three FAP patients were identified. Diagnosis was made by colonoscopy (69%) or genetic screening (25%) at mean age of 12.5 years. Most children (58%) were asymptomatic and diagnosed via screening due to family history. Rectal bleeding was the most common (37%) symptom prompting evaluation. Colon polyps appeared by mean age of 13.4 years with > 50 polyps at the time of diagnosis in 60%. Cancer was found in 1 colonoscopy biopsy and 5 colectomy specimens. Family history of FAP was known in 85%. 53% had genetic testing, which confirmed APC mutation in 88%. Extraintestinal manifestations included congenital hypertrophy of the retinal pigment epithelium (11.3%), desmoids (10.6%), osteomas (6.7%), epidermal cysts (5.5%), extranumerary teeth (3.7%), papillary thyroid cancer (3.1%), and hepatoblastoma (2.5%). Six patients died secondary to FAP.
Clinical presentation and manifestations in pediatric FAP are variable. We suggest an individualized patient-oriented screening algorithm that allows for earlier screening and appropriate management.
Endoscopic Management of Upper Gastrointestinal Familial Adenomatous Polyposis Syndrome and Ampullary Tumors
2011, Clinical Gastrointestinal Endoscopy, Second Edition
Colonic Polyps and Polyposis Syndromes
2010, Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print
Colorectal Cancer: Pathogenesis and Risk Factors
2009, CT Colonography: Principles and Practice of Virtual Colonoscopy
Gastrointestinal oncology. What should be the monitoring strategy for duodenal adenomas in familial adenomatous polyposis?
2008, Gastroenterologia y Hepatologia

View all citing articles on Scopus

View full text

Upper intestinal surveillance in familial adenomatous polyposis

Abstract

Lancet

Gastroenterology

Lancet

Gastroenterology

Cell

Gastroenterology

Gastroenterology

Gastroenterology

Cell

Gastroenterology

Gastroduodenal polyps in patients with familial adenomatous polyposis

Dis Colon Rectum

Gastroduodenal polyps in familial polyposis coli

Dis Colon Rectum

Gastroduodenal polyps in familial adenomatous and juvenile polyposis

Endoscopy

Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps

Gut

Risk of gastric cancer among Korean familial adenomatous polyposis (FAP) patients (meeting abstract)

The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs: its rational treatment

Ann Surg

Gastric lesions of familial polyposis coli

Cancer

The upper gastrointestinal tract